anti-human CD17, Clone MEM-74
Description
CD17, lactosylceramide, is an ubiquitous glycosphingolipid with uncharged disaccharide headgroup, highly enriched in lipid raftderived structures. Besides playing a pivotal role in the biosynthesis of complex glycosphingilipids, lactosylceramide is involved in cellcell and cellmatrix interactions and in signaling events linked to cell differentiation, development, apoptosis and oncogenesis. Lactosylceramide regulates integrin functions and production of nitric oxide. Its expression defines successive stages in the maturation of myeloid cells. Lactosylceramide (LaCer) is present on peripheral blood granulocytes including basophils, monocytes, platelets and a subset of B cells (40-80% CD19+). In tissues, CDw17 is found on tonsillar dendritic cells, epithelial cells, intestinal epithelium and endothelial. CDw17 antigen may play a role in phagocytosis.
Properties
The monoclonal antibody ADG5011/L (clone MEM-74) is a murine monoclonal antibody, subclass IgM. The antibody has been purified ascites by gel filtration and precipitation methods, Purity > 95% (by SDS-PAGE). The antibody recognizes CDw17, a membrane lipid moiety lactosylceramide expressed on granulocytes, monocytes and platelets
Presentation
Vial containing 100 µg /100 µl (ADG5011) or 300 µg/ 300 µl (ADG5011L) of purified antibody in PBS containing 0.09 % sodium azide (pH 7.2). The IgG concentration is 1 mg/ml. Spin the vial briefly before opening.
Storage and Stability
Store at 4 °C. For longterm storage aliquot and store at -20°. It is recommended to avoid freeze-thaw cycles. The reagent is stable until the expiry date stated on the vial label.
Applications
Flow Cytometry
Category: Research use only
Type: Antibody
Product Availability: Worldwide
Manufacturer: ImmBioMed GmbH & Co KG, Germany
For more information please click .pdf icon below.
anti-human CD17, Clone MEM-74
Cat.No. ADG5011L
Artikelnr.: 938015
Einheit: 300 µg
Code: ADG5011L
Hersteller: ImmBioMed GmbH & Co. KG
References
- J Biol Chem. 2013 Aug 9;288(32):23264-72. doi: 10.1074/jbc.M113.491431. Epub 2013 Jun 25.
Lactosylceramide interacts with and activates cytosolic phospholipase A2α.
Nakamura H, Moriyama Y, Makiyama T, Emori S, Yamashita H, Yamazaki R, Murayama T.
CD17 also known as lactosylceramide (LacCer) is a bioactive lipid in various cell physiological processes. The authors provided evidence that LacCer (CD17) is a direct activator of cytosolic phospholipase A2α (cPLA2α).
- Arterioscler Thromb Vasc Biol. 1998 Oct;18(10):1523-33.
Sphingolipids in atherosclerosis and vascular biology.
Chatterjee S
In his review Chatterjee refers to the observation that sphingolipids and their metabolic products have second-messenger functions in a variety of cellular signaling pathways. Lactosylceramide (LacCer; CD17) mediates the tumor necrosis factor-alpha (TNF-alpha)-induced nuclear factor-kappaB expression and intercellular adhesion molecule (ICAM-1) expression in vascular endothelial cells. Moreover, LacCer (CD17) also stimulates the expression of CD11/CD8, or Mac-1, on the surface of human neutrophils. This may promote the adhesion of neutrophils or monocytes to the endothelial cell surface and initiate the process of atherosclerosis. Moreover, there is evidence that plaque stability may be negatively affected by LacCer (CD17). The author concludes that “The findings … indicate an important role for sphingolipids in vascular biology and provide an exciting opportunity for further research in vascular disease and atherosclerosis.”
- Leucocyte Typing IV. Knapp W et al. (Eds.), Oxford University Press (1989)
- Horejsi V. et al., Folia Biol. (Praha) 34, 23 (1988)
- J Lipid Res. 1973 Jan;14(1):16-25.
Sphingolipid composition of human platelets.
Tao RV, Sweeley CC, Jamieson GA.
In this seminal publication Tao and colleagues identified lactosylceramide (CD17) as a major glycosphingolipid in platelets. They conclude that “the presence of a relatively high proportion of ceramide in platelets may be a unique characteristic of this cellular fraction of blood.”